Tag: Biotech & Pharma
-
The EQT Qiagen Takeover: A 10 Billion Euro Test of Private Capital
An EQT-led consortium with ADIA and CPP Investments has agreed a 46.50 euro per share offer for Qiagen, a 40.3 per cent premium valuing the diagnostics group at roughly 12 billion dollars with debt. Inside the EQT Qiagen takeover: the coalition doing the buying, the German mechanics, and what it signals for every derated quality…
-
The mRNA Cancer Vaccine Breakthrough: $92 Billion Repriced on a Result Nobody Has Seen
Moderna and Merck’s personalised mRNA cancer vaccine met its goals in the Phase 3 INTerpath-001 melanoma trial, the first late-stage success for the technology. Roughly $92 billion of market value moved on an announcement that contained no efficacy figure at all.